“Quarterly or even biannual dosing alone would be transformative for patients living with AD, and the durability and efficacy demonstrated in APEX Phase 2 Part A through one year makes the profile for ...
DURHAM, N.C., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a clinical-stage gene therapy company focused on using the life-changing power of genetic medicine to reverse or prevent blindness, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results